AstraZeneca has announced a $100 million research investment to strategically boost work in the infectious disease area and continue its incremental growth in cancer research at its research center near Boston, Massachusetts.
The expansion of AstraZeneca's research facility will accommodate up to 100 additional researchers. They would join the more than 400 existing employees who are focused on discovering treatments for infectious diseases and cancer.
"This investment will significantly boost our research capabilities in two critical areas of medical need, and two areas where we have tremendous heritage," said David Brennan, Chief Executive Officer of AstraZeneca. "It will provide additional resources for our scientists who are tackling more complex diseases than ever before, as they work towards our ultimate goal of giving people hope for a healthier future."
Adds Jan Lundberg, Executive Vice President, AstraZeneca Global Discovery Research, "Infectious disease is becoming more prevalent and problematic to patients and healthcare providers, placing a heavy burden on our healthcare systems. With our expanded presence in Boston, our scientists will be better equipped to discover and develop novel medicines to address important areas of unmet need."